These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36298832)

  • 1. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
    Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
    Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R
    Transpl Int; 2024; 37():12061. PubMed ID: 38328617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tixagevimab-cilgavimab as pre-exposure prophylactic treatment against SARS-CoV-2 in kidney transplantation patients].
    Bravo González-Blas L; Menéndez García N; Fernández Prada M; Gago Fraile M; Suárez Fernández ML; Ridao Cano N
    Nefrologia (Engl Ed); 2024; 44(3):396-401. PubMed ID: 38331599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.
    Simone S; Pronzo V; Pesce F; Bavaro DF; Infante B; Mercuri S; Schirinzi A; Panaro A; Conte E; Belati A; Troise D; Pontrelli P; Conserva F; Gallo P; Panico M; Spilotros M; Lucarelli G; Saracino A; Stallone G; Di Serio F; Ditonno P; Gesualdo L
    J Nephrol; 2024 Jul; 37(6):1539-1550. PubMed ID: 38780697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.
    Basoulis D; Mastrogianni E; Karamanakos G; Gkoufa A; Georgakopoulou VE; Makrodimitri S; Gamaletsou MN; Markogiannakis A; Sipsas NV
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
    Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
    Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
    Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
    Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
    Schiaroli E; Gidari A; Brachelente G; Bicchieraro G; Spaccapelo R; Bastianelli S; Pierucci S; Busti C; Pallotto C; Malincarne L; Camilloni B; Falcinelli F; De Socio GV; Villa A; Mencacci A; Francisci D
    J Clin Virol; 2023 Nov; 168():105584. PubMed ID: 37778220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Yan VKC; Yang Y; Wan EYF; Lai FTT; Chui CSL; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Drug Saf; 2024 Oct; 47(10):1025-1037. PubMed ID: 38916712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
    Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
    Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
    Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
    Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
    Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
    J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan.
    Taniguchi T; Homma T; Tamai Y; Arita Y; Fujiwara M; Kuroishi N; Sugiyama K; Kanazu S; Maruyama A
    J Infect Chemother; 2024 Jul; ():. PubMed ID: 38986842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.